ALCLS shifts focus to in vivo gene editing for dyslipidemias
The company said it is pivoting to in vivo gene editing and advancing.HEAL-101 and.HEAL-201 for severe dyslipidemias, with first clinical data expected in 2027–2028.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.